N-acetyl-4--L-phenylalanine | 107173-63-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-acetyl-4--L-phenylalanine
• 英文别名: N-acetyl melphalan；N-Acetyl-3-(4--phenyl)-α-alanin；(2S)-2-acetamido-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
• CAS: 107173-63-7
• 化学式: C₁₅H₂₀Cl₂N₂O₃
• 分子量: 347.241
• InChiKey: NZEYWBNQKCRBFO-AWEZNQCLSA-N

物化性质

• 熔点：
  153-154 °C
• 沸点：
  586.2±50.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-acetyl-4--L-phenylalanine 生成 (2S)-2-acetamido-3-[4-[bis(2-chloroethyl)amino]phenyl]-N-methyl-N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]propanamide
  参考文献：
  名称：

  VASINA, O. S.;KROTOVA, V. I.;KONOVALOVA, A. L.;MARTYNOV, V. S.;SHKODINSKA+

  摘要：

  DOI：
• 作为产物：
  描述：

  美法仑 在 乙酸酐 、 sodium carbonate 、 柠檬酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 N-acetyl-4--L-phenylalanine
  参考文献：
  名称：

  Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

  摘要：

  这项发明涉及一种用于增强治疗剂效的化合物识别方法。该方法包括将化合物孵育在血细胞中；将免疫细胞与红细胞分离；并确定免疫细胞中化合物浓度与红细胞中化合物浓度的比率；其中该化合物包括一种传输体和一种治疗剂，其中传输体通过键或链接物与治疗剂共价结合。

  公开号：

  US20040005641A1

文献信息

• HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS
  申请人：Yu Chongxi

  公开号：US20100069336A1

  公开（公告）日：2010-03-18

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明提供了新型高渗透性组合物（HPC）或高渗透性前药（HPP）芥末及芥末相关化合物的组合物，其能够高效地穿过生物屏障。HPP能够在穿过生物屏障后转化为母体活性药物或药物代谢物，从而可以治疗母体药物或代谢物所能治疗的疾病。此外，HPP能够到达母体药物无法进入或无法在目标区域产生足够浓度的区域，从而提供新型治疗方法。HPP可以通过各种给药途径给予受试者，例如，局部给药于高浓度的病变部位或经系统给药于生物体内，并以更快的速率进入循环系统。
• De Castiglione; Gozzini; Galantino, Il Farmaco, 1992, vol. 47, # 6, p. 855 - 867
  作者：De Castiglione、Gozzini、Galantino、Corradi、Ciomei、Roletto、Bertolero

  DOI：——

  日期：——
• POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF MUSTARDS AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES
  申请人：Techfields Biochem Co. Ltd

  公开号：EP2077991B1

  公开（公告）日：2014-02-26
• HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS
  申请人：Yu, Chongxi

  公开号：EP2370406A1

  公开（公告）日：2011-10-05
• [EN] HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS<br/>[FR] COMPOSITIONS À PÉNÉTRATION ÉLEVÉE ET LEURS APPLICATIONS
  申请人：YU CHONGXI

  公开号：WO2010065936A1

  公开（公告）日：2010-06-10

  High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e. g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.